Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness and safety of forodesine in CLL patients

Detailed Description
-----------------
To investigate the efficacy (complete response [CR] + partial response [PR]) of forodesine in treating subjects with CLL who have failed at least one prior treatment regimen or who are treatment naïve but are either elderly, have poor performance status or are otherwise predicted not to tolerate cytotoxic chemotherapy.

Official Title
-----------------
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Conditions
-----------------
Chronic Lymphocytic Leukemia (CLL)

Intervention / Treatment
-----------------
* Drug: forodesine HCl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and older Diagnosis of CLL established by peripheral blood and/or bone marrow examination and using the standard diagnostic criteria. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by the 1996 National Cancer Institute -Working Group (NCI-WG) criterion Primary resistant (no CR or PR) or progressive disease after response to at least one prior treatment regimen OR treatment naïve subjects who meet at least one of the following criteria. age >65 years Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4 Inability to tolerate standard cytotoxic chemotherapy in the opinion of the treating physician. ECOG performance status of 0, 1, or 2 (for subjects with primary resistance or progressive disease after response to at least one prior treatment regimen). Willing to take adequate contraceptive measures (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after, except for patients who are post menopausal or have prior hysterectomy. All investigational treatments should have been discontinued for at least 3 weeks prior to the initiation of the study drug. Exclusion Criteria: Pregnant or nursing. Unable or unwilling to sign consent. Severe, ongoing co-morbid conditions, which would preclude safe delivery of the investigational therapy. Active serious infections that are not controlled by antibiotics. ECOG performance status >2 (except for treatment naïve subjects where ECOG performance status 0, 1 or 5 is excluded). Inadequate renal function: creatinine > or equal to 2.0 unless related to the disease. Inadequate liver function: bilirubin > or equal to 3.0; transaminases > or equal to 3.0 times the upper limit of normal unless related to the disease. Known positive test for human immunodeficiency virus (HIV). Subjects with known hepatitis B and/or hepatitis C active infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: forodesine HCl|2 x 100mg capsules daily|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate |  | Up to 6 cycles of therapy |